BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35665338)

  • 1. Clinicopathological Implications of the
    Zurnadzhy L; Bogdanova T; Rogounovitch TI; Ito M; Tronko M; Yamashita S; Mitsutake N; Bolgov M; Chernyshov S; Masiuk S; Saenko VA
    Front Med (Lausanne); 2022; 9():882727. PubMed ID: 35665338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The
    Zurnadzhy L; Bogdanova T; Rogounovitch TI; Ito M; Tronko M; Yamashita S; Mitsutake N; Chernyshov S; Masiuk S; Saenko VA
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
    Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
    Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary Thyroid Carcinoma in Ukraine After Chernobyl and in Japan After Fukushima: Different Histopathological Scenarios.
    Bogdanova TI; Saenko VA; Hashimoto Y; Hirokawa M; Zurnadzhy LY; Hayashi T; Ito M; Iwadate M; Mitsutake N; Rogounovitch TI; Sakamoto A; Naganuma H; Miyauchi A; Tronko MD; Thomas G; Yamashita S; Suzuki S
    Thyroid; 2021 Sep; 31(9):1322-1334. PubMed ID: 33143557
    [No Abstract]   [Full Text] [Related]  

  • 5. The relationship of the clinicopathological characteristics and treatment results of post-Chornobyl papillary thyroid microcarcinomas with the latency period and radiation exposure.
    Bogdanova T; Chernyshov S; Zurnadzhy L; Rogounovitch TI; Mitsutake N; Tronko M; Ito M; Bolgov M; Masiuk S; Yamashita S; Saenko VA
    Front Endocrinol (Lausanne); 2022; 13():1078258. PubMed ID: 36589808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Histopathologic Analysis of "Radiogenic" and "Sporadic" Papillary Thyroid Carcinoma: Patients Born Before and After the Chernobyl Accident.
    Bogdanova TI; Saenko VA; Brenner AV; Zurnadzhy LY; Rogounovitch TI; Likhtarov IA; Masiuk SV; Kovgan LM; Shpak VM; Thomas GA; Chanock SJ; Mabuchi K; Tronko MD; Yamashita S
    Thyroid; 2018 Jul; 28(7):880-890. PubMed ID: 29989861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation induced thyroid cancer: fundamental and applied aspects.
    Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
    Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
    Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
    Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl.
    Mitsutake N; Fukushima T; Matsuse M; Rogounovitch T; Saenko V; Uchino S; Ito M; Suzuki K; Suzuki S; Yamashita S
    Sci Rep; 2015 Nov; 5():16976. PubMed ID: 26584635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
    Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort.
    Bogdanova TI; Zurnadzhy LY; Nikiforov YE; Leeman-Neill RJ; Tronko MD; Chanock S; Mabuchi K; Likhtarov IA; Kovgan LM; Drozdovitch V; Little MP; Hatch M; Zablotska LB; Shpak VM; McConnell RJ; Brenner AV
    Br J Cancer; 2015 Dec; 113(11):1556-64. PubMed ID: 26625214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.